LungLife AI, Inc.(the “Company” or “LungLife”) Successful validation of LungLB® in multi-site, prospective clinical study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces the successful validation of its LungLB® test for indeterminate lung nodules from a prospective, multi-site clinical study in the clinically important small […]
LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]